Personalization of Therapy to Optimize Outcomes for Men with Prostate Cancer - Interview with Felix Feng

(Length of Conversation: 10 min)

Felix Feng, MD talks with Alicia Morgans, MD, MPH on identifying subsets of patients with prostate cancer that are most responsive to certain therapies so the physician can better individualize treatment options for patients. Topics they discuss include predictive biomarkers, hormone therapy, early initiation of hormone therapy for patients treated with surgery up front.  In addition, they also discussed salvage radiation therapy and the RTOG-9601 study published in the New England Journal of Medicine, where the addition of two years of anti-androgen therapy to salvage radiation improved survival for patients with PSA recurrence after prostatectomy.

Biographies: 
Felix Y. Feng MD, Associate Professor of Radiation Oncology; Urology; and Medicine, Vice Chair for Faculty Development and Director of Translational Research, Department of Radiation Oncology at the University of California of San Francisco

Alicia Morgans, MD, MPH

Read More:
Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.